Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 133 of 151

  1. UC-GIG-2023

    Ningbo Cancer Hospital

    Patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. UC-GIG-2308

    Ningbo Cancer Hospital

    Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment

    phase 2 small molecule active

    1 trial

  3. UC-GIG-2311

    Ningbo Cancer Hospital

    Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

    phase 2 small molecule active

    1 trial

  4. UC-GIG-2404

    Ningbo Cancer Hospital

    Advanced biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  5. UC-GIG-2411

    Ningbo Cancer Hospital

    Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)

    phase 2 small molecule active

    1 trial

  6. UC-GMP-2504

    Ningbo Cancer Hospital

    Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting

    phase 2 small molecule active

    1 trial

  7. UC-IMM-2302

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  8. UC-IMM-2509/2510

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  9. UC-IMM-2511/2512

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

  10. UC-MSC transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 other active

    1 trial

  11. UC-MSCs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cirrhosis Due to Hepatitis B

    phase 2 mab active

    1 trial

  12. UC-SAR-2212_L-UteCIN

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  13. UCAB-CT-05

    COGNITION THERAPEUTICS INC

    Primary biliary cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  14. UC_0160/1406

    Ningbo Cancer Hospital

    Penis carcinoma

    phase 2 small molecule active

    1 trial

  15. UID 4270

    Istituto Gentili S.r.l.

    Metastatic hormone receptor-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  16. UK-453,061 Dose 1

    Pfizer

    HIV-1

    phase 2 small molecule terminated

    1 trial

  17. UKD-IKF-Double-T

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  18. UKT-IKF-DEPECA-1

    The George Institute

    locally advanced or metastatic penile squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  19. UP-CLI-2023-01

    Lacuna Pharma Pty Ltd

    to obtain pre-operative mydriasis or for diagnostic purposes

    phase 2 small molecule active

    1 trial

  20. URSODEOXYCHOLIC ACID

    The George Institute

    Hepatorenal polycystic diseases

    phase 2 small molecule active

    1 trial

  21. US-guided RFA

    The First People's Hospital of Lianyungang

    Liver Cancer

    phase 2 other active

    1 trial

  22. US-guided laser ablation for refractory neoplasms

    The First People's Hospital of Lianyungang

    Refractory Neoplasms

    phase 2 other active

    1 trial

  23. UT-15C

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 2 small molecule completed

    1 trial

  24. UX003

    Ultragenyx UK Limited

    Mucopolysaccharidosis Type 7

    phase 2 small molecule completed

    1 trial

  25. UX007

    Ultragenyx UK Limited

    Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

    phase 2 small molecule completed

    1 trial

  26. UX007

    Ultragenyx UK Limited

    Glucose Transporter Type 1 Deficiency Syndrome

    phase 2 small molecule terminated

    1 trial

  27. UX007

    Ultragenyx UK Limited

    Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency

    phase 2 small molecule completed

    1 trial

  28. UX016

    Ultragenyx UK Limited

    GNE Myopathy

    phase 2 small molecule active

    1 trial

  29. UX053

    Ultragenyx UK Limited

    Glycogen Storage Disease Type III

    phase 2 mab terminated

    1 trial

  30. UX701

    Ultragenyx UK Limited

    Wilson Disease

    phase 2 gene therapy active

    1 trial

  31. Ubamatamab

    Regeneron UK Limited

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  32. Ubamatamab

    Regeneron UK Limited

    Advanced/Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  33. Ubamatamab

    Regeneron UK Limited

    Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  34. Ubamatamab

    Regeneron UK Limited

    SMARCB1-Deficient Malignancies

    phase 2 small molecule active

    1 trial

  35. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Remitting Multiple Sclerosis

    phase 2 mab completed

    1 trial

  36. Ublituximab

    TG THERAPEUTICS, INC.

    Non-Hodgkins Lymphoma

    phase 2 small molecule completed

    2 trials

  37. Ublituximab

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  38. Ublituximab

    TG THERAPEUTICS, INC.

    Autoimmune Disorders

    phase 2 small molecule active

    1 trial

  39. Ublituximab

    TG THERAPEUTICS, INC.

    multiple sclerosis

    phase 2 small molecule active

    1 trial

  40. Udenafil

    Takeda

    Erectile Dysfunction

    phase 2 small molecule terminated

    2 trials

  41. Ultravist /ml soluzione iniettabile for breast pathology

    Fondazione Telethon ETS

    breast pathology

    phase 2 small molecule active

    1 trial

  42. Ultravist 370 mg/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    Patients with breast lesions undergoing further examination

    phase 2 small molecule active

    1 trial

  43. Umbilical Cord Blood Infusion

    Hospital Authority, Hong Kong

    Cerebral Palsy

    phase 2 mab terminated

    1 trial

  44. Umbilical Cord Mesenchymal Stem Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Spinal Cord Injury

    phase 2 small molecule active

    1 trial

  45. Umbilical Cord Mesenchymal Stem Cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Spinal Cord Injuries

    phase 2 small molecule active

    2 trials

  46. Umbralisib

    TG THERAPEUTICS, INC.

    Marginal Zone Lymphoma

    phase 2 small molecule completed

    1 trial

  47. Umbralisib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    4 trials

  48. Umbralisib

    TG THERAPEUTICS, INC.

    Lymphoma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.